PMID- 27338643
OWN - NLM
STAT- MEDLINE
DCOM- 20170405
LR  - 20181202
IS  - 1724-6008 (Electronic)
IS  - 0393-6155 (Linking)
VI  - 31
IP  - 4
DP  - 2016 Dec 23
TI  - ALK immunohistochemistry for ALK gene rearrangement screening in non-small cell 
      lung cancer: a systematic review and meta-analysis.
PG  - e413-e421
LID - EC854003-9EE4-4E48-80DC-D4FC188AD206 [pii]
LID - 10.5301/jbm.5000218 [doi]
AB  - INTRODUCTION: The aim of this study was to investigate the diagnostic accuracy of 
      anaplastic lymphoma kinase (ALK) immunohistochemistry (IHC) for ALK gene 
      rearrangement in non-small cell lung cancer (NSCLC) through systematic review, 
      meta-analysis and diagnostic test accuracy review. METHODS: The current study 
      included 11,806 NSCLC cases in 42 eligible studies. We performed concordance 
      analyses between ALK IHC and fluorescence in situ hybridization (FISH). The 
      diagnostic accuracy of ALK IHC was analyzed based on ALK IHC criteria and 
      antibodies. RESULTS: The overall ALK IHC results were positive in 13.2%. The 
      overall concordance rate between ALK IHC and FISH was 0.950 (95% confidence 
      interval [CI], 0.927-0.966). In the ALK IHC-positive and negative groups, the 
      concordance rates were 0.805 (95% CI 0.733-0.861) and 0.985 (95% CI 0.978-0.990), 
      respectively. The ALK FISH-positive rates were 0.009 (95% CI 0.004-0.023), 0.378 
      (95% CI 0.217-0.572), 0.628 (95% CI 0.420-0.796) and 0.900 (95% CI 0.840-0.939) 
      in the ALK IHC 0, 1+, 2+ and 3+ groups, respectively. In diagnostic test accuracy 
      review for ALK IHC, the pooled sensitivity and specificity were 0.92 (95% CI 
      0.89-0.94) and 0.91 (95% CI 0.90-0.91), respectively. The diagnostic odds ratio 
      and the area under the curve on the summary receiver operating characteristic 
      curve were 266.56 (95% CI 110.83-641.14) and 0.983, respectively. CONCLUSIONS: 
      Our results suggested that ALK IHC equivocal (score 1+ and 2+) cases should not 
      be considered as IHC-negative in screening for ALK gene rearrangement. Additional 
      detailed criteria for ALK IHC equivocal cases are necessary to determine how to 
      best apply this approach in daily practice.
FAU - Pyo, Jung-Soo
AU  - Pyo JS
AD  - Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School 
      of Medicine, Seoul - Republic of Korea.
AD  - Department of Pathology, Eulji University Hospital, Daejeon, Republic of Korea.
FAU - Kang, Guhyun
AU  - Kang G
AD  - Department of Pathology, Inje University Sanggye Paik Hospital, Seoul - Republic 
      of Korea.
FAU - Sohn, Jin Hee
AU  - Sohn JH
AD  - Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School 
      of Medicine, Seoul - Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20161223
PL  - United States
TA  - Int J Biol Markers
JT  - The International journal of biological markers
JID - 8712411
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Anaplastic Lymphoma Kinase
MH  - Carcinoma, Non-Small-Cell Lung/*enzymology/*genetics/pathology
MH  - Early Detection of Cancer
MH  - Gene Rearrangement
MH  - Humans
MH  - Immunohistochemistry
MH  - Lung Neoplasms/*enzymology/*genetics/pathology
MH  - Receptor Protein-Tyrosine Kinases/*genetics
EDAT- 2016/10/30 06:00
MHDA- 2017/04/06 06:00
CRDT- 2016/06/25 06:00
PHST- 2016/05/27 00:00 [accepted]
PHST- 2016/10/30 06:00 [pubmed]
PHST- 2017/04/06 06:00 [medline]
PHST- 2016/06/25 06:00 [entrez]
AID - EC854003-9EE4-4E48-80DC-D4FC188AD206 [pii]
AID - 10.5301/jbm.5000218 [doi]
PST - epublish
SO  - Int J Biol Markers. 2016 Dec 23;31(4):e413-e421. doi: 10.5301/jbm.5000218.